We’re big fans of the American Society of Clinical Oncology (ASCO) conferences every year. And that’s because every time we trade presenter stocks, we do quite well. This year should be no different.
But because of recent market volatility, we’re limiting the number of ASCO trades to two this year. They include Karyopharm Therapeutics (KPTI) and Advaxis (ADXS). Both have pulled back, giving us attractive buys.
Both are presenting data at the conference that should increase money flow into both underlying stocks.
Here are the trades:
• Buy to open the ADXS July 2014 2.50 calls up to 80 cents.
ADXS – a developer of next generation cancer immunotherapies – will present two abstracts related to the company’s immunotherapy candidate. According to the latest press release, we’ll hear about:
ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer; A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265);
• With KPTI, no options are available. But we still like it. Buy the stock up to $27.
According to the latest release, “Clinical and preclinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)…”
“Clinical results to be presented include updated data from Karyopharm's Phase 1 studies in patients with advanced hematologic malignancies, solid tumors and sarcomas.”